Insilico Medicine Reports First Profit and $106.3M Revenue in H1 2026

Insilico Medicine recorded a net profit of $35.54 million and an adjusted net profit of $51.23 million in the first half of 2026. [1] This marks the first time an AI-driven drug discovery company of its profile has reported full-period profitability. [1] The results were shared in the company's first interim report since listing on the Hong Kong Stock Exchange at the end of 2025. [1]

Of the $106.3 million in total revenue, $103.1 million came from drug discovery and pipeline development, which increased more than 300% year over year. [1] This revenue was primarily driven by large upfront payments from new business development deals and milestone payments from existing collaborations, while software solutions revenue reached $2.70 million. [1] The company's total announced contract value for transactions in 2026 reached approximately $7.3 billion. [1] Notable agreements include a $2.5 billion collaboration with SK Biopharmaceuticals announced in June 2026, and an approximately $600 million collaboration with Takeda Pharmaceutical in July 2026. [1]

The financial results demonstrate that AI drug discovery platforms can achieve profitability through aggressive licensing and partnership models, rather than relying solely on software sales or fully self-developed commercial therapies. The disparity between Insilico's $103.1 million in pipeline revenue and $2.70 million in software revenue underscores that large pharmaceutical companies are primarily willing to pay for tangible drug assets and milestone-driven collaborations. However, because upfront and milestone payments are episodic, sustaining this profitability will require a continuous pipeline of new deals or successful clinical advancements. What the sources don't address: How much ongoing capital Insilico will need to fund the internal development of its own clinical assets alongside these partnered programs.